Imidazole carboxamide (DTIC) in the treatment of advanced lymphomas. Efficacy of DTIC in cases which fail to respond to conventional chemotherupetic combinations.
15 patients with malignant lymphomas (stage III B or IV) who had become resistant to previous combination chemotherapy were treated with DTIC. The drug was administered intravenously as a single agent in doses of 300 mg/m2 on 5 consecutive days, once a month. The results demonstrate good responses in Hodgkin's disease, while in non-Hodgkin's lymphomas only incomplete and short remissions or failures were recorded. The only untoward side effects were nausea, vomiting and pain in the vein during the injection.
D000328:Adult; D001761:Bleomycin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009150:Mustard Compounds / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D014226:Triazenes / Q000627:therapeutic use*; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D009150:Mustard Compounds; D014226:Triazenes; D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D003520:Cyclophosphamide; D011239:Prednisolone; D011241:Prednisone; D008727:Methotrexate